Cargando…
LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro
AIMS/HYPOTHESIS: Activation of inflammatory pathways is involved in the pathogenesis of type 2 diabetes mellitus. On the basis of its role in vascular inflammation and in metabolic disorders, we hypothesised that the TNF superfamily (TNFSF) member 14 (LIGHT/TNFSF14) could be involved in the pathogen...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016561/ https://www.ncbi.nlm.nih.gov/pubmed/27421726 http://dx.doi.org/10.1007/s00125-016-4036-y |
_version_ | 1782452582251233280 |
---|---|
author | Halvorsen, Bente Santilli, Francesca Scholz, Hanne Sahraoui, Afaf Gulseth, Hanne L. Wium, Cecilie Lattanzio, Stefano Formoso, Gloria Di Fulvio, Patrizia Otterdal, Kari Retterstøl, Kjetil Holven, Kirsten B. Gregersen, Ida Stavik, Benedicte Bjerkeli, Vigdis Michelsen, Annika E. Ueland, Thor Liani, Rossella Davi, Giovanni Aukrust, Pål |
author_facet | Halvorsen, Bente Santilli, Francesca Scholz, Hanne Sahraoui, Afaf Gulseth, Hanne L. Wium, Cecilie Lattanzio, Stefano Formoso, Gloria Di Fulvio, Patrizia Otterdal, Kari Retterstøl, Kjetil Holven, Kirsten B. Gregersen, Ida Stavik, Benedicte Bjerkeli, Vigdis Michelsen, Annika E. Ueland, Thor Liani, Rossella Davi, Giovanni Aukrust, Pål |
author_sort | Halvorsen, Bente |
collection | PubMed |
description | AIMS/HYPOTHESIS: Activation of inflammatory pathways is involved in the pathogenesis of type 2 diabetes mellitus. On the basis of its role in vascular inflammation and in metabolic disorders, we hypothesised that the TNF superfamily (TNFSF) member 14 (LIGHT/TNFSF14) could be involved in the pathogenesis of type 2 diabetes mellitus. METHODS: Plasma levels of LIGHT were measured in two cohorts of type 2 diabetes mellitus patients (191 Italian and 40 Norwegian). Human pancreatic islet cells and arterial endothelial cells were used to explore regulation and relevant effects of LIGHT in vitro. RESULTS: Our major findings were: (1) in both diabetic cohorts, plasma levels of LIGHT were significantly raised compared with sex- and age-matched healthy controls (n = 32); (2) enhanced release from activated platelets seems to be an important contributor to the raised LIGHT levels in type 2 diabetes mellitus; (3) in human pancreatic islet cells, inflammatory cytokines increased the release of LIGHT and upregulated mRNA and protein levels of the LIGHT receptors lymphotoxin β receptor (LTβR) and TNF receptor superfamily member 14 (HVEM/TNFRSF14); (4) in these cells, LIGHT attenuated the insulin release in response to high glucose at least partly via pro-apoptotic effects; and (5) in human arterial endothelial cells, glucose boosted inflammatory response to LIGHT, accompanied by an upregulation of mRNA levels of HVEM (also known as TNFRSF14) and LTβR (also known as LTBR). CONCLUSIONS/INTERPRETATION: Our findings show that patients with type 2 diabetes mellitus are characterised by increased plasma LIGHT levels. Our in vitro findings suggest that LIGHT may contribute to the progression of type 2 diabetes mellitus by attenuating insulin secretion in pancreatic islet cells and by contributing to vascular inflammation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-016-4036-y) contains peer-reviewed but unedited supplementary material, which is available to authorised users. |
format | Online Article Text |
id | pubmed-5016561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-50165612016-09-19 LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro Halvorsen, Bente Santilli, Francesca Scholz, Hanne Sahraoui, Afaf Gulseth, Hanne L. Wium, Cecilie Lattanzio, Stefano Formoso, Gloria Di Fulvio, Patrizia Otterdal, Kari Retterstøl, Kjetil Holven, Kirsten B. Gregersen, Ida Stavik, Benedicte Bjerkeli, Vigdis Michelsen, Annika E. Ueland, Thor Liani, Rossella Davi, Giovanni Aukrust, Pål Diabetologia Article AIMS/HYPOTHESIS: Activation of inflammatory pathways is involved in the pathogenesis of type 2 diabetes mellitus. On the basis of its role in vascular inflammation and in metabolic disorders, we hypothesised that the TNF superfamily (TNFSF) member 14 (LIGHT/TNFSF14) could be involved in the pathogenesis of type 2 diabetes mellitus. METHODS: Plasma levels of LIGHT were measured in two cohorts of type 2 diabetes mellitus patients (191 Italian and 40 Norwegian). Human pancreatic islet cells and arterial endothelial cells were used to explore regulation and relevant effects of LIGHT in vitro. RESULTS: Our major findings were: (1) in both diabetic cohorts, plasma levels of LIGHT were significantly raised compared with sex- and age-matched healthy controls (n = 32); (2) enhanced release from activated platelets seems to be an important contributor to the raised LIGHT levels in type 2 diabetes mellitus; (3) in human pancreatic islet cells, inflammatory cytokines increased the release of LIGHT and upregulated mRNA and protein levels of the LIGHT receptors lymphotoxin β receptor (LTβR) and TNF receptor superfamily member 14 (HVEM/TNFRSF14); (4) in these cells, LIGHT attenuated the insulin release in response to high glucose at least partly via pro-apoptotic effects; and (5) in human arterial endothelial cells, glucose boosted inflammatory response to LIGHT, accompanied by an upregulation of mRNA levels of HVEM (also known as TNFRSF14) and LTβR (also known as LTBR). CONCLUSIONS/INTERPRETATION: Our findings show that patients with type 2 diabetes mellitus are characterised by increased plasma LIGHT levels. Our in vitro findings suggest that LIGHT may contribute to the progression of type 2 diabetes mellitus by attenuating insulin secretion in pancreatic islet cells and by contributing to vascular inflammation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-016-4036-y) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2016-07-15 2016 /pmc/articles/PMC5016561/ /pubmed/27421726 http://dx.doi.org/10.1007/s00125-016-4036-y Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Article Halvorsen, Bente Santilli, Francesca Scholz, Hanne Sahraoui, Afaf Gulseth, Hanne L. Wium, Cecilie Lattanzio, Stefano Formoso, Gloria Di Fulvio, Patrizia Otterdal, Kari Retterstøl, Kjetil Holven, Kirsten B. Gregersen, Ida Stavik, Benedicte Bjerkeli, Vigdis Michelsen, Annika E. Ueland, Thor Liani, Rossella Davi, Giovanni Aukrust, Pål LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro |
title | LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro |
title_full | LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro |
title_fullStr | LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro |
title_full_unstemmed | LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro |
title_short | LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro |
title_sort | light/tnfsf14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016561/ https://www.ncbi.nlm.nih.gov/pubmed/27421726 http://dx.doi.org/10.1007/s00125-016-4036-y |
work_keys_str_mv | AT halvorsenbente lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT santillifrancesca lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT scholzhanne lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT sahraouiafaf lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT gulsethhannel lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT wiumcecilie lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT lattanziostefano lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT formosogloria lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT difulviopatrizia lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT otterdalkari lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT retterstølkjetil lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT holvenkirstenb lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT gregersenida lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT stavikbenedicte lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT bjerkelivigdis lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT michelsenannikae lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT uelandthor lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT lianirossella lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT davigiovanni lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro AT aukrustpal lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro |